TICKERNERD
Menu
UPCUPCHealthcare · Drug Manufacturers - Specialty & Generic

UPC Stock Forecast: Universe Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$4.31

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 7 Oct 2026 — in the lower half.

Market cap
$21.2M
Ticker Nerd rank
32 / 100
Median analyst target
—
Analysts covering
—
Ticker Nerd rank

UPC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Universe Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Growth
63
Momentum
57
Quality
52
Value
38
Accruals
33
Issuance
28
Revisions
25
Volatility
8

Size (87): Smaller than most of the companies we track.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

UPC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UPC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UPC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

UPC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Universe Pharmaceuticals, Inc. (UPC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
1.2×

Cheaper than 64% of US stocks

Price / book
0.0×

Cheaper than 91% of US stocks

EV / EBITDA
10.6×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
−1.3%

Higher than 25% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−16.6%

Higher than 22% of US stocks

Net margin
−10.9%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−3.5%

Higher than 41% of US stocks

Return on assets
−1.7%

Higher than 38% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Universe Pharmaceuticals, Inc. (UPC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Universe Pharmaceuticals, Inc. has a market value of $21.2M and an enterprise value of −$17.1M.

  • Shares outstanding: 647,838.

  • Trailing P/E: −0.5×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Universe Pharmaceuticals, Inc. employs 216 people.

market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

UPC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
UPCUniverse Pharmaceuticals, Inc.$21.2M
32
AYTUAytu Biopharma, Inc.$22.0M
88
SHPHShuttle Pharmaceuticals Holdings, Inc.$22.4M
17
TXMDTherapeuticsMD, Inc.$23.1M
78
OPTHOptimi Health Corp.$23.7M
10
RMTIRockwell Medical, Inc.$32.4M
53
BFRIBiofrontera, Inc.$13.9M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Universe Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UPC news & analysis

The Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC.

Business Wire · 7 Oct 2026negative

The Law Offices of Frank R. Cruz said it is investigating potential claims against Universe Pharmaceuticals’ board of directors over whether the board breached fiduciary duties to shareholders. The notice invites shareholders who meet its stated share-purchase timing to discuss the matter.

Why it matters — The investigation concerns potential board duties to UPC shareholders, a matter relevant to investors following the company.

FAQ

Frequently asked questions about UPC stock

How does Ticker Nerd's model rank UPC?

As at 7 Oct 2026, Universe Pharmaceuticals, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

What is the UPC stock forecast for 2030?

No analyst covering Universe Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPC are extrapolating price history, which says nothing about the business.

What does Universe Pharmaceuticals, Inc. do?

Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products.

What is the latest news on UPC?

The most recent item we track (Business Wire, 7 Oct 2026): "The Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC.". The Law Offices of Frank R. Cruz said it is investigating potential claims against Universe Pharmaceuticals’ board of directors over whether the board breached fiduciary duties to shareholders. The notice invites shareholders who meet its stated share-purchase timing to discuss the matter.

Company

About Universe Pharmaceuticals, Inc.

Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. The company also offers biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements sourced from third-party manufacturers. Its product portfolio is designed to address common health conditions, including chronic ailments associated with aging, as well as cold and flu needs. Operating through its subsidiaries, Universe Pharmaceuticals serves customers in domestic and international markets and participates in the broader healthcare supply chain through production, distribution, and commercialization activities. Headquartered in Ji’an, Jiangxi, China, the company issues Class A ordinary shares as part of a dual-class share structure that is used in its corporate governance framework.

CEO Mr. Gang Lai · 216 employees · China · https://www.universe-pharmacy.com